SEC Filings

Form 6-K
MESOBLAST LTD filed this Form 6-K on 06/01/2018
Document Outline
Entire Document (4429.4 KB)
Subdocument 1 - 6-K - 6-K
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - QUARTERLY REPORT ON FORM 6-K
Page 4 - N/A
Page 5 - The above consolidated income statement should be read in conjunction with the accompanying Notes.
Page 6 - The above consolidated statement of comprehensive income should be read in conjunction with the acco
Page 7 - The above consolidated statement of changes in equity should be read in conjunction with the accompa
Page 8 - The above consolidated balance sheet should be read in conjunction with the accompanying Notes.
Page 9 - The above consolidated statement of cash flows should be read in conjunction with the accompanying N
Page 10 - 1. Basis of preparation
Page 11 - N/A
Page 12 - 2. Significant changes in the current reporting period
Page 13 - 3. Loss before income tax
Page 14 - 4. Income tax benefit/(expense)
Page 15 - 5. Financial assets and liabilities
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - Level 1
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - 6. Non-financial assets and liabilities
Page 24 - 7. Cash flow information
Page 25 - 8. Issued capital
Page 26 - N/A
Page 27 - N/A
Page 28 - 10. Losses per share
Page 29 - 11. Events occurring after the reporting period
Page 30 - MANAGEMENT S DISCUSSION AND ANALYSIS OF
Page 31 - Circulation
Page 32 - Arthritis Research Therapy
Page 33 - Mergers and Acquisitions
Page 34 - Interest Revenue.
Page 35 - Finance Costs.
Page 36 - Revenue
Page 37 - Manufacturing commercialization
Page 38 - Management and administration
Page 39 - Other operating income and expenses
Page 40 - Loss after income tax
Page 41 - Results of Operations:
Page 42 - Research and development
Page 43 - Manufacturing commercialization
Page 44 - Fair value remeasurement of contingent consideration
Page 45 - Finance costs
Page 46 - Liquidity and Capital Resources
Page 47 - Net cash outflows in investing activities
Page 48 - Contractual Obligations and Commitments
Page 49 - Certain Differences Between IFRS and GAAP
Page 50 - Revenue Recognition
Page 51 - Government grant income
Page 52 - Current marketed products
Page 53 - Investments and other financial assets
Page 54 - Borrowings
Page 55 - Net deferred tax assets
Page 56 - RISK FACTORS
Page 57 - We require substantial additional financing to achieve our goals, and our failure to obtain this nec
Page 58 - The terms of our loan facility with Hercules Capital, Inc. ( Hercules ) could restrict our operation
Page 59 - We may encounter substantial delays in our clinical studies.
Page 60 - We may participate in multinational clinical trials, which present additional and unique risks.
Page 61 - Several of our product candidates treat patients who are extremely ill, and patient deaths that occu
Page 62 - N/A
Page 63 - Our drug candidates may not benefit from an expedited approval path for cellular medicines designate
Page 64 - Ethical and other concerns surrounding the use of embryonic stem cell-based therapy may negatively a
Page 65 - Breakthrough therapy designation by the FDA may not lead to a faster development or regulatory revie
Page 66 - Our existing product development and/or commercialization arrangements, and any that we may enter in
Page 67 - Risks Related to Our Manufacturing and Supply Chain
Page 68 - We may not be able to manufacture or commercialize our product candidates in a profitable manner.
Page 69 - We and our collaborators depend on a limited number of suppliers for our product candidates material
Page 70 - We will rely on third parties to perform many necessary services for the commercialization of our pr
Page 71 - If, in the future, we are unable to establish our own sales, marketing and distribution capabilities
Page 72 - Our marketed products may be used by physicians for indications that are not approved by the FDA. If
Page 73 - Due to the novel nature of our stem cell therapy and the potential for our product candidates to off
Page 74 - We are exposed to risks related to our international operations, and failure to manage these risks m
Page 75 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 76 - The patent positions of biopharmaceutical products are complex and uncertain.
Page 77 - Intellectual property disputes could cause us to spend substantial resources and distract our person
Page 78 - If third parties claim that intellectual property used by us infringes upon their intellectual prope
Page 79 - Our employees, principal investigators, consultants and collaboration partners may engage in miscond
Page 80 - We work with outside scientists and their institutions in developing product candidates. These scien
Page 81 - Taxing authorities could reallocate our taxable income within our subsidiaries, which could increase
Page 82 - A failure to adequately protect private health information could result in severe harm to our reputa
Page 83 - If we fail to maintain proper internal controls, our ability to produce accurate financial statement
Page 84 - Risks Related to Our Trading Markets
Page 85 - If securities or industry analysts do not publish research reports about our business, or if they is
Page 86 - As a foreign private issuer, we are permitted and expect to follow certain home country corporate go
Page 87 - If we are or become classified as a passive foreign investment company, our U.S. securityholders may
Page 88 - U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or
Page 89 - Signatures

Share Price ASX: MSB  AUD 1.14 as of Dec 14, 2018